Also known as: MCC
Merkel cell carcinoma is a rare, aggressive neuroendocrine skin cancer with high risk of recurrence and metastasis. It often appears in sun-exposed skin and is associated with advanced age, immunosuppression, and Merkel cell polyomavirus.
A novel therapeutic vaccine using structural nanomedicine principles has shown promising results against HPV-driven cancers in preclinical models. The spherical nucleic acid vaccine design significantly slowed tumor growth and extended survival by generating potent T-cell responses. Unlike preventive HPV vaccines, this approach is designed to treat established cancers caused by the virus.
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
Two clinical trials demonstrate efficacy of talimogene laherparepvec (T-VEC) oncolytic virus therapy in HER2-negative breast cancer and nonmelanoma skin cancers, with favorable safety profiles and durable responses in subset of patients.
TuHURA Biosciences filed an IND application with the FDA for TBS-2025, a VISTA inhibiting antibody, to be studied in combination with a menin inhibitor for treating mutNPM1 relapsed/refractory Acute Myeloid Leukemia.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07472322 |
ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07288073 |
TIL Therapy in cSCC and MCC |
RECRUITING | PHASE2 |
| NCT07285044 |
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas |
RECRUITING | PHASE2 |
| NCT07115043 |
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT06939036 |
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) |
TERMINATED | PHASE1/PHASE2 |
| NCT06814496 |
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT06753136 |
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype |
RECRUITING | NA |
| NCT06536257 |
Personalised Immunotherapy Platform |
RECRUITING | |
| NCT06448611 |
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma |
NOT_YET_RECRUITING | |
| NCT06223659 |
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers |
RECRUITING | PHASE2 |
